Recent submissions
Now showing items 221-240 of 889
-
Predictive and prognostic transcriptomic biomarkers in soft tissue sarcomas.
(NATURE PORTFOLIO, 2021-03-05)Soft tissue sarcomas (STS) are rare and heterogeneous tumours comprising over 80 different histological subtypes. Treatment options remain limited in advanced STS with high rates of recurrence following resection of localised ... -
Development of biomarker assays to dissect subtype-specific heterogeneity and anti-EGFR treatment response in colorectal cancer
(Institute of Cancer Research (University Of London), 2020-08-31)Colorectal cancer (CRC) is the third most frequently diagnosed type of cancer and the second leading cause of cancer deaths worldwide. Although extensive biological heterogeneity at multiple "-omics" levels has been ... -
PD-L1 Multiplex and Quantitative Image Analysis for Molecular Diagnostics.
(MDPI, 2020-12-23)Multiplex immunofluorescence (mIF) and digital image analysis (DIA) have transformed the ability to analyse multiple biomarkers. We aimed to validate a clinical workflow for quantifying PD-L1 in non-small cell lung cancer ... -
Metastasis and Immune Evasion from Extracellular cGAMP Hydrolysis.
(AMER ASSOC CANCER RESEARCH, 2021-05-01)Cytosolic DNA is characteristic of chromosomally unstable metastatic cancer cells, resulting in constitutive activation of the cGAS-STING innate immune pathway. How tumors co-opt inflammatory signaling while evading immune ... -
Assessment of Ki67 in Breast Cancer: Updated Recommendations from the International Ki67 in Breast Cancer Working Group.
(2020-12-28)Ki67 immunohistochemistry, commonly used as a proliferation marker in breast cancer, has limited value for treatment decisions due to questionable analytical validity. The International Ki67 Working Group (IKWG) consensus ... -
MNK Inhibition Sensitizes KRAS-Mutant Colorectal Cancer to mTORC1 Inhibition by Reducing eIF4E Phosphorylation and c-MYC Expression.
(AMER ASSOC CANCER RESEARCH, 2021-05-01)KRAS-mutant colorectal cancers are resistant to therapeutics, presenting a significant problem for ∼40% of cases. Rapalogs, which inhibit mTORC1 and thus protein synthesis, are significantly less potent in KRAS-mutant ... -
A blood transcriptome-based analysis of disease progression, immune regulation, and symptoms in coronavirus-infected patients.
(SPRINGERNATURE, 2020-12-08)COVID-19 patients show heterogeneity in clinical presentation and outcomes that makes pandemic control and strategy difficult; optimizing management requires a systems biology approach of understanding the disease. Here ... -
Defective ALC1 nucleosome remodeling confers PARPi sensitization and synthetic lethality with HRD.
(CELL PRESS, 2021-02-18)Chromatin is a barrier to efficient DNA repair, as it hinders access and processing of certain DNA lesions. ALC1/CHD1L is a nucleosome-remodeling enzyme that responds to DNA damage, but its precise function in DNA repair ... -
Clinical and co-clinical genomics of paediatric solid tumours with a special focus in DIPG
(Institute of Cancer Research (University Of London), 2020-07-31)Cure rates for paediatric solid cancers have not improved in the last decade. Delivering precision medicine to stratify patients based on their molecular profiling is a key goal to support existing and upcoming adaptive ... -
Abiraterone in "High-" and "Low-risk" Metastatic Hormone-sensitive Prostate Cancer.
(ELSEVIER, 2019-12-01)BACKGROUND: Abiraterone acetate received licencing for use in only "high-risk" metastatic hormone-naïve prostate cancer (mHNPC) following the LATITUDE trial findings. However, a "risk"-related effect was not seen in the ... -
Genomic and transcriptomic heterogeneity in metaplastic carcinomas of the breast.
(NATURE PUBLISHING GROUP, 2017-12-01)Metaplastic breast cancer (MBC) is a rare special histologic type of triple-negative breast cancer, characterized by the presence of neoplastic cells showing differentiation towards squamous epithelium and/or mesenchymal ... -
DECONVOLVING CONVOLUTIONAL NEURAL NETWORK FOR CELL DETECTION
(IEEE, 2019-01-01) -
Artificial intelligence and digital pathology: Opportunities and implications for immuno-oncology.
(ELSEVIER, 2021-02-06)The field of immuno-oncology has expanded rapidly over the past decade, but key questions remain. How does tumour-immune interaction regulate disease progression? How can we prospectively identify patients who will benefit ... -
Olaparib and temozolomide in desmoplastic small round cell tumors: a promising combination in vitro and in vivo.
(SPRINGER, 2020-07-01)PURPOSE: Desmoplastic small round cell tumors (DSRCTs) are highly malignant and very rare soft tissue sarcomas with a high unmet need for new therapeutic options. Therefore, we examined poly(ADP-ribose) polymerase 1 (PARP1) ... -
EGFR Blockade Reverts Resistance to KRASG12C Inhibition in Colorectal Cancer.
(AMER ASSOC CANCER RESEARCH, 2020-08-01)Most patients with KRAS G12C-mutant non-small cell lung cancer (NSCLC) experience clinical benefit from selective KRASG12C inhibition, whereas patients with colorectal cancer bearing the same mutation rarely respond. To ... -
A Review of Clinical Practice Guidelines and Treatment Recommendations for Cancer Care in the COVID-19 Pandemic.
(MDPI, 2020-08-29)The COVID-19 pandemic has inevitably caused those involved in cancer care to change clinical practice in order to minimize the risk of infection while maintaining cancer treatment as a priority. General advice during the ... -
Vault RNAs: hidden gems in RNA and protein regulation.
(SPRINGER BASEL AG, 2020-10-15)Non-coding RNAs are important regulators of differentiation during embryogenesis as well as key players in the fine-tuning of transcription and furthermore, they control the post-transcriptional regulation of mRNAs under ... -
Sirolimus for patients with progressive epithelioid hemangioendothelioma.
(WILEY, 2020-10-27)Epithelioid hemangioendothelioma is an ultrarare soft tissue sarcoma with limited literature to guide treatment. The results from a robust retrospective cohort study support the use of sirolimus for patients who have ...